A Study to Evaluate the Efficacy and Safety of CEP-33457 in Patients With Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of a 200-mcg dose of
CEP-33457 compared with placebo in patients with active systemic lupus erythematosus (SLE) as
assessed by the proportion of patients achieving a combined clinical response using the SLE
responder index (SRI) at week 24.